<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855123</url>
  </required_header>
  <id_info>
    <org_study_id>LEGENDRE APJ 2019</org_study_id>
    <nct_id>NCT04855123</nct_id>
  </id_info>
  <brief_title>Evaluation of the Degradation of Renal Function Post Nephrectomy According to Retinal Vascularisation Parameters</brief_title>
  <acronym>NEPHRIN</acronym>
  <official_title>Evaluation of the Degradation of Renal Function Post Nephrectomy According to Retinal Vascularisation Parameters &quot;NEPHRIN&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney failure in the single remaining kidney is one of the dreaded complications of&#xD;
      nephrectomy in patients operated on for cancer-related reasons (1). Indeed, chronic kidney&#xD;
      disease (CKD) is associated with major cardiovascular morbidity and mortality (2).&#xD;
&#xD;
      To date, there are few non-invasive methods available to predict the onset and progression of&#xD;
      CKD in patients for whom nephrectomy is indicated. Preoperative creatinine and glomerular&#xD;
      filtration rate are poor predictors of the subsequent risk of single kidney failure (1).&#xD;
      Early predictive markers could help anticipate the management of CKD in patients for whom&#xD;
      progression to end-stage renal disease is predictable. Furthermore, such markers could be&#xD;
      used as a decision-making aid to specify the type of nephrectomy to be preferred (total&#xD;
      versus partial nephrectomy).&#xD;
&#xD;
      The state of microcirculation, particularly retinal, is correlated with the progression of&#xD;
      certain conditions such as diabetic nephropathy (3-5). A new technique for evaluating retinal&#xD;
      microcirculation called OCT-A (an imaging technique in ophthalmology allowing a precise&#xD;
      non-invasive study of the retinal microvascular network) has recently been used by our team&#xD;
      to highlight an association between retinal vascularisation and the level of cardiovascular&#xD;
      risk in a population of coronary patients without diabetes (6).&#xD;
&#xD;
      We hypothesize that the observation of retinal vascular abnormalities could reflect changes&#xD;
      in kidney structure that could underlie chronic renal failure. The aim of this work is thus&#xD;
      to evaluate whether the presence of abnormalities in the retinal microvascularisation is 1)&#xD;
      predictive of the deterioration in renal function one year after nephrectomy for&#xD;
      cancer-related reasons and 2) correlated with renal histological abnormalities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline in renal function one year after nephrectomy</measure>
    <time_frame>One year after nephrectomy</time_frame>
    <description>defined in a given patient as the occurrence of a Glomerular Filtration Flow Rate (CKD/EPI equation) of less than 60ml/min/1.73 m2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Nephrostomy</condition>
  <condition>Retinal Vascularisation</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>retinal imaging</intervention_name>
    <description>OCT-angiography, Retinophotography, ocular fundus, Pulsed air tonometer</description>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>paraclinical surveillance</intervention_name>
    <description>blood and urine sampling, assessment of kidney function with creatinine, protein, albumin levels and CKD-EPI equation)</description>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient&#xD;
&#xD;
          -  Indication for total nephrectomy for kidney cancer decided with a multidisciplinary&#xD;
             oncology consultation&#xD;
&#xD;
          -  Kidney scan images available&#xD;
&#xD;
          -  Patient affiliated to French national health insurance&#xD;
&#xD;
          -  Patient who has given oral consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Ophthalmologic history (macular vascular or degenerative diseases, epiretinal&#xD;
             membranes, glaucoma)&#xD;
&#xD;
          -  Cannot sit still for 60 minutes&#xD;
&#xD;
          -  Metastatic cancer&#xD;
&#xD;
          -  Thrombosis of the renal vein&#xD;
&#xD;
          -  Single functional kidney before nephrectomy&#xD;
&#xD;
          -  Estimated Glomerular Filtration Flow Rate (CKD-EPI formula) less than 60 mL/min/1.73m2&#xD;
&#xD;
          -  Diabetes type 1 or type 2&#xD;
&#xD;
          -  Proteinuria at inclusion (or in the 3 months prior to inclusion) on sample with a&#xD;
             protein/creatinuria ratio greater than 1g/g or over 24 hours greater than 1g/day&#xD;
&#xD;
          -  HIV, HCV or HBV positive serology&#xD;
&#xD;
          -  Patient subject to a measure of legal protection (guardianship, curatorship, etc.)&#xD;
&#xD;
        SECONDARY EXCLUSION CRITERIA&#xD;
&#xD;
          -  Patient with increased pressure during the measurement of the intraocular pressure&#xD;
             before dilation&#xD;
&#xD;
          -  Patient with histological abnormalities suggestive of nephropathy (excluding&#xD;
             nephroangiosclerosis) in the pathological analysis of the nephrectomy sample&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu LEGENDRE</last_name>
    <phone>03.80.29.37.56</phone>
    <phone_ext>+33</phone_ext>
    <email>mathieu.legendre@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu LEGENDRE</last_name>
      <phone>03.80.29.37.56</phone>
      <email>mathieu.legendre@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

